In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Cancer Genetics, Inc.. Trade Record

NASDAQ:CGIX Cancer Genetics, Inc. stock gains 5.77% Exit Apr 10, 2019 a Trade Record by priceseries

Trade Chart
Trade Chart CGIX Apr 5, 2019, priceSeries
About Cancer Genetics, Inc.

Cancer Genetics, Inc. develops, commercializes, and provides molecular and biomarker-based tests and services in the United States, India, and China. Its tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biotech and pharmaceutical companies involved in oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. The company's clinical services provide information on diagnosis, prognosis, and predicting treatment outcomes of cancers to guide patient management. Its biopharma services offer companies with customized solutions for patient stratification and treatment selection through a suite of molecular- and biomarker-based testing services, customized assay development, and trial design consultation. The company's discovery services provide the tools and testing methods for companies and researchers to identify new molecular-based biomarkers for disease. It serves hospitals, cancer centers, clinics, academic institutions, and government-sponsored research institutions, as well as pharmaceutical and biotech companies performing clinical trials. The company collaborates with oncology centers and community-based hospitals to develop its proprietary diagnostic tests. Cancer Genetics, Inc. was founded in 1999 and is based in Rutherford, New Jersey.

Trade Information
Trade Type
LONG
ReliabilityScore™
89.61
Entry Date
Apr 5, 2019
Entry Price
7.80
Sell Date
Apr 10, 2019
Sell Price
8.25
Net Gain
5.77%
Hold Time
3 Trading Days